

Ostomy Care Continence Care Wound & Skin Care Interventional Urology

# Coloplast – transactions in connection with share buy-back programme, week 29

As mentioned in Announcement no. 02/2021 Coloplast is initiating a share buyback programme totalling up to DKK 500 million.

The programme commenced on 22 February 2021 and is expected to end by 23 August 2021.

The share buyback programme is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations with the purpose of meeting obligations arising from share options programmes or other allocation of shares to employees or to complete a share capital decrease as set out in Articles 5(2)(a) and 5(2)(c) in MAR.0

Date Number of shares Average purchase Transaction value, DKK price, DKK 19 July 2021 200 1,091.04 218,208 20 July 2021 300 1,093.04 327,912 21 July 2021 11,000 1,100.55 12,106,050 22 July 2021 150 1,103.17 165,476 23 July 2021 300 1,117.02 335,106 Accumulated until now 411,048 975.29 400,891,662 under the programme

The following transactions have been executed during the period 19 – 23 July 2021:

Henceforth, Coloplast owns 3,229,384 treasury B shares of DKK 1 equal to 1.50% of the company's total share capital.

An overview showing the transaction data for the period 19 – 23 July 2021 is enclosed.

Kind regards, Investor Relations Coloplast A/S Tel. +45 4911 1800 Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Tel: +45 4911 1111 www.coloplast.com Company reg. (CVR) no. 69749917 Announcement 26 July 2021



Ostomy Care Continence Care Wound & Skin Care Interventional Urology

#### **Our mission**

Making life easier for people with intimate healthcare needs

## **Our values**

Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

## Our vision

Setting the global standard for listening and responding

## For further information, please contact

## Investors and analysts

Anders Lonning-Skovgaard Executive Vice President, CFO Tel. +45 4911 1111

Ellen Bjurgert Vice President, Investor Relations Tel. +45 4911 1800 /+45 4911 3376 Email: dkebj@coloplast.com

Aleksandra Dimovska Sr. Manager, Investor Relations Tel. +45 4911 1800 /+45 4911 2458 Email: dkadim@coloplast.com

## Press and the media

Peter Mønster Sr. Media Relations Manager Tel. +45 4911 2623 Email: dkpete@coloplast.com

## Address

Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917

## Website

www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate health care. Our business includes Ostomy Care, Continence Care, Wound and Skin Care and Interventional Urology. We operate globally and employ about 12,500 employees.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2021-07. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark

Investor Relations Tel. +45 4911 1800 Fax +45 4911 1555 www.coloplast.com Comp. reg. (CVR). 69749917